Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27583
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGan, Hui K-
dc.contributor.authorParakh, Sagun-
dc.contributor.authorLassman, Andrew B-
dc.contributor.authorSeow, Aidan-
dc.contributor.authorLau, Eddie-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorAmeratunga, Malaka-
dc.contributor.authorPerchyonok, Yuliya-
dc.contributor.authorCao, Diana-
dc.contributor.authorBurvenich, Ingrid J G-
dc.contributor.authorO'Keefe, Graeme J-
dc.contributor.authorRigopoulos, Angela-
dc.contributor.authorGomez, Erica-
dc.contributor.authorMaag, David-
dc.contributor.authorScott, Andrew M-
dc.date2021-01-
dc.date.accessioned2021-09-27T05:17:06Z-
dc.date.available2021-09-27T05:17:06Z-
dc.date.issued2021-08-03-
dc.identifier.citationNeuro-Oncology Advances 2021; 3(1): vdab102en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27583-
dc.description.abstractThe adverse impact of increasing brain tumor size on the efficacy of antibody-drug conjugates (ADCs) was investigated preclinically then validated with clinical data. The impact of tumor size on ADC tumor delivery and treatment response was evaluated in an EGFR-amplified patient-derived glioblastoma (GBM) model following treatment with Depatuxizumab mafadotin (Depatux-M). Biodistribution and imaging studies correlated drug distribution with starting treatment volume and anti-tumor activity. M12-356 was a Phase I study of Depatux-M in patients with GBM. Blinded volumetric analysis of baseline tumor volumes of M12-356 patients was undertaken by two reviewers and results correlated with response and survival. Preclinically, imaging and biodistribution studies showed specific and significantly higher tumor uptake of zirconium-89 labeled Depatux-M (89Zr-Depatux-M) in mice with smaller tumor volume (~98 mm3) versus those with larger volumes (~365 mm3); concordantly, mice with tumor volumes ≤100 mm3 at treatment commencement had significantly better growth inhibition by Depatux-M (93% vs 27%, P < .001) and significantly longer overall survival (P < .0001) compared to tumors ≥400 mm3. Clinically, patients with tumor volumes <25 cm3 had significantly higher response rates (17% vs. 0%, P = .009) and longer overall survival (0.5 vs 0.89 years, P = .001) than tumors above 25 cm3. Both preclinical and clinical data showed intra-tumoral concentration and efficacy of Depatux-m inversely correlated with tumor size. This finding merit further investigation with pretreatment tumor volume as a predictor for response to ADCs, in both gliomas and other solid tumors.en
dc.language.isoeng
dc.subjectGBMen
dc.subjectdepatuxizumab mafadotinen
dc.subjecttumor volumeen
dc.titleTumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeuro-Oncology Advancesen
dc.identifier.affiliationResearch and Development Department, AbbVie Inc., North Chicago, Illinois, USAen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, Australiaen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationDivision of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, NY, USAen
dc.identifier.affiliationRadiologyen
dc.identifier.affiliationDepartment of Medical Oncology, Monash Health, Clayton, Melbourne, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, Heidelberg, Melbourne, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.doi10.1093/noajnl/vdab102en
dc.type.contentTexten
dc.identifier.orcid0000-0001-7319-8546en
dc.identifier.pubmedid34549181
local.name.researcherGan, Hui K
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
crisitem.author.deptRadiology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptRadiology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Feb 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.